Captrust Financial Advisors Erasca, Inc. Transaction History

Captrust Financial Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$4.58 - $8.72 $2,303 - $4,386	503 Added 474.53%	609 $3,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $911 - $1,640	106 New	106 $1,000
Q4 2021 Feb 14, 2022	SELL	$12.51 - $22.75 $625 - $1,137	-50 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$17.43 - $24.34 $871 - $1,217	50 New	50 $1,000

117

74.3M

7.1K

40.1K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $287M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.